跳至主要内容
临床试验/NCT04056026
NCT04056026已完成早期 1 期

A Single Dose FMT Infusion From a Healthy Family Donor Via Colonoscopy as an Adjunct to Keytruda for the Benefit of Improving Efficacy of Immunotherapy for Metastatic Mesothelioma

ProgenaBiome2 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2018年9月18日最近更新:
适应症

试验速览

阶段
早期 1 期
状态
已完成
发起方
入组人数
1
试验地点
2
主要终点
Progression free survival

研究概览

简要总结

The investigators propose to ensure a favorable gut microbiome by fecal microbiota transplant to enhance the efficacy Keytruda

详细描述

Studies have shown that a favorable microbiome can be the difference between response and non-response of certain cancer treatments such as PD-1 blockade inhibitors. As such the investigators propose to ensure a favorable microbiome in this patient by fecal microbiota transplant to enhance the efficacy of such a drug, Keytruda.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient with metastatic mesothelioma deemed a candidate for PD-1 blockade inhibitor therapy

排除标准

  • Patient unable/unwilling to comply with protocol
  • Patient deemed not a candidate for PD-1 Blockade inhibitor therapy

结局指标

主要结局

Progression free survival

时间窗: Five years

The time from transplant that the patient's tumors remain stable or shrink.

次要结局

未报告次要终点

研究者

发起方
ProgenaBiome
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验